Last updated on May 2020

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065


Brief description of study

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC.

This study consists of three sub-studies: Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic.

Clinical Study Identifier: NCT03398135

Find a site near you

Start Over

Allergy & Immunology (AIU) /ID# 171439

Cape Town, South Africa
2.49miles
  Connect »

Dr JP Wright /ID# 171142

Cape Town, South Africa
4.2miles
  Connect »

Mediclinic Constantiaberg /ID# 171141

Cape Town, South Africa
5.52miles
  Connect »